Bionano Genomics, Inc. (BNGO)

Bionano Genomics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-232.49	-132.6	-72.44	-41.11	-29.82
Depreciation & Amortization	13.97	10.32	4.04	1.48	1.13
Share-Based Compensation	15.18	22.42	9.72	1.55	1.35
Other Operating Activities	78.17	-24.96	-13.25	-0.24	-2.19
Operating Cash Flow	-125.18	-124.82	-71.93	-38.31	-29.53
Capital Expenditures	-1.69	-3.17	-2.07	0	-0.06
Acquisitions	0.1	-30.65	-49.09	-2.45	0
Change in Investments	25.75	116.69	-226.91	0	0
Other Investing Activities	-	-0.1	-	-	-
Investing Cash Flow	24.16	82.77	-278.06	-2.45	-0.06
Share Issuance / Repurchase	56.38	23.04	351.12	66.63	20.56
Debt Issued / Paid	66.43	-0.04	-15.01	-4.72	9.82
Other Financing Activities	-9	-	-	-	-
Financing Cash Flow	113.82	23.01	336.11	61.9	30.38
Exchange Rate Effect	0.07	-0.04	0	0	0
Net Cash Flow	12.86	-19.08	-13.88	21.14	0.79
Free Cash Flow	-126.87	-127.99	-73.99	-38.31	-29.59
Free Cash Flow Margin	-351.29%	-460.36%	-411.51%	-450.59%	-292.12%
Free Cash Flow Per Share	-3.71	-4.43	-2.67	-3.67	-19.76

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).